Using a non-magnetic screen to guide breathing during MRI-guided radiotherapy for mobile cancerous lesions
Official title: Impact of Non-magnetic Screen Respiratory Self-guidance During MRI-guided Radiotherapy Sessions for Mobile Lesions
Run by Centre Georges Francois Leclerc · NCT05783908 · Data updated 2026-11-12
This study is testing if using a special non-magnetic screen during MRI-guided radiotherapy can help patients with mobile cancerous lesions breathe better and improve their treatment experience.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Months and up |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Centre Georges Francois Leclerc Academic / other |
| Locations | 1 site (Dijon, Côte d'Or) |
| Status | Recruiting |
| Started | October 16, 2023 |
| Main results expected | September 27, 2025 |
| Study ends | September 27, 2025 |
| Registry record updated | February 17, 2025 |
| Trial ID | NCT05783908 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 and older who are starting radiotherapy on Linac MRI for mobile cancerous lesions.
✕Probably not a fit
Patients with lesions not detectable by the tracking system or those with contraindications to MRI treatment may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the impact of a non-magnetic screen on patient breathing guidance during MRI-guided radiotherapy sessions for mobile cancerous lesions, such as those in the pancreas, liver, kidneys, and adrenals. Patients will be randomized into two groups: one receiving standard treatment without the screen and the other with the screen in place. The study aims to assess whether the screen can reduce the discrepancy between actual and predicted treatment times. Participants will undergo five sessions of radiotherapy, with evaluations of anxiety, stress, patient satisfaction, pain intensity, and respiratory effort conducted throughout the treatment period.
Why it matters
Potential benefit: If successful, this approach could enhance the efficiency of radiotherapy sessions and improve patient comfort and outcomes.
How similar studies have gone: While the specific use of a non-magnetic screen in this context is novel, similar approaches in improving patient guidance during radiotherapy have shown promise in other studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient is at least 18 years old * Patient starting radiotherapy on Linac MRI for a mobile cancerous lesion most often in the pancreas, liver, kidneys, adrenals, lung, supra or subdiaphragmatic adenopathy * Patient affiliated to the social security system Exclusion Criteria: * Patient with lesions not detected by the device's tracking system * Patient with visual disturbances * Contraindications to treatment with Linac MRI (epileptic patients, pregnant or breastfeeding women, metallic prosthesis or pacemaker not compatible with MRI) * Patients with cognitive disorders * Persons deprived of liberty or under guardianship (including curatorship) * Pregnant or nursing woman * Refusal to participate in the study
Where it's running
-
Centre Georges-François Leclerc
Dijon, Côte d'Or, France Recruiting
Study contacts
- Study coordinator: Gilles TRUC, Doctor
- Email: gtruc@cgfl.fr
- Phone: 03 80 73 75 18
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Predicting who responds to anti-PD-1/PD-L1 therapy using blood extracellular vesicle tests
This study tests whether immune biomarkers found in blood extracellular vesicles can predict who with NSCLC or unresectable melanoma will respond to anti-PD-1/PD-L1 therapies.
-
Understanding Cancer Patients' Preferences for Genetic Information Before Exome Analysis
This study is trying to find out how cancer patients want to receive genetic information before they have a specific genetic test, to make sure they understand their treatment options better.
-
Ultra-rapid testing for BRCA1/2 mutations in breast cancer patients
This study tests a fast BRCA1/2 mutation screening for breast cancer patients to see if it can reduce their waiting time for results and help ease their anxiety.
-
Evaluating FOLFIRINOX treatment for advanced pancreatic cancer
This study is testing if a specific chemotherapy called FOLFIRINOX can help people with advanced pancreatic cancer feel better and live longer compared to other treatments.
-
Evaluating a new treatment for advanced lung cancer with low PD-L1 levels
This study is testing a new treatment combining mirdametinib and chemotherapy for people with advanced lung cancer and low PD-L1 levels to see if it helps them.
-
Monitoring immune responses in breast cancer patients during treatment
This study is testing how different treatments for breast cancer affect the immune system by collecting blood samples from women during their therapy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.